Effects of Intramuscular Testosterone Undecanoate on Body Composition and Bone Mineral Density in Female-to-Male Transsexuals

Journal of Sexual Medicine

Volumn 7, Issue 9, 2010, Pages 3190-3198

  Mueller, Andreas ^a   Haeberle, Lothar ^a   Zollver, Hendryk ^a   Claassen, Tomma ^a   Kronawitter, Desiree ^a   Oppelt, Patricia G ^a   Cupisti, Susanne ^a   Beckmann, Matthias W ^a   Dittrich, Ralf ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Body composition; Bone mineral density; Cross sex hormone treatment; Testosterone therapy in female to male transsexuals; Transsexuals

Indexed keywords

ALANINE AMINOTRANSFERASE; ESTRADIOL; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; GONADOTROPIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL;

ACNE; ADULT; AGGRESSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; CLITORIS; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; ENDOMETRIAL DISEASE; FEMALE; FEMALE TO MALE TRANSSEXUAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAIR GROWTH; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSTILITY; HUMAN; HYPERSEXUALITY; LEAN BODY WEIGHT; LIBIDO; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MORBIDITY; MORTALITY; OVARY DISEASE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE; VOICE CHANGE;

EID: 77956284511     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01912.x     Document Type: Article

References (56)

1. Hamburger C. Endocrine treatment of male and female transsexualism. Transsexualism and sex reassignment 1969, 291-307. Green RMoney J. eds., Baltimore, MD, Johns Hopkins Press
2. Standards of Care, 6th version. 2008, http://www.wpath.org/publications_standards.cfm, The World Professional Association for Transgender Health, Available at: (accessed June 9, 2010
3. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, Tangpricha V, Montori VM. Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009, 94:3132-54. Endocrine Society
4. Klein C, Gorzalka BB. Sexual functioning in transsexuals following hormone therapy and genital surgery: A review. J Sex Med 2009, 11:2922-39.
5. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: A review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003, 88:3467-73.
6. Futterweit W. Endocrine management of transsexual. Hormonal profiles of serum prolactin, testosterone, and estradiol. N Y State J Med 1980, 80:1260-4.
7. Asscheman H, Gooren LJ, Eklund P. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 1989, 38:869-73.
8. Van Kesteren P, Asscheman H, Megens J, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997, 47:337-42.
9. Michel A, Mormont C, Legros J. A psycho-endocrinological overview of transsexualism. Eur J Endocrinol 2001, 145:365-76.
10. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003, 59:409-18.
11. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008, 159:197-202.
12. Gooren LJ. Hormone treatment of the adult transsexual patient. Horm Res 2005, 64(2):31-6. suppl
13. Harle L, Basaria S, Dobs AS. Nebido: A long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005, 6:1751-9.
14. Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 2006, 24:639-44.
15. Nieschlag E. Testosterone treatment comes of age: New options for hypogonadal men. Clin Endocrinol (Oxf) 2006, 65:275-81.
16. Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren LJ, Nieschlag E. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007, 9:291-7.
17. Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med 2007, 4:1479-84.
18. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007, 92:3470-5.
19. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol 2009, 161:795-8.
20. Meriggiola MC, Armillotta F, Costantino A, Altieri P, Saad F, Kalhorn T, Perrone AM, Ghi T, Pelusi C, Pelusi G. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med 2008, 5:2442-53.
21. Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C, Meriggiola MC. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009, 6:3193-200.
22. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005, 113:586-92.
23. Kronawitter D, Gooren LJ, Zollver H, Oppelt PG, Beckmann MM, Dittrich R, Mueller A. Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: Results of a pilot study. Eur J Endocrinol 2009, 161:363-8.
24. Mueller A, Dittrich R, Binder H, Kuehnel W, Maltaris T, Hoffmann I, Beckmann MW. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 2005, 153:107-13.
25. Mueller A, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Dittrich R. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals. Horm Metab Res 2006, 38:183-7.
26. Cupisti S, Dittrich R, Binder H, Kajaia N, Hoffmann I, Maltaris T, Beckmann MW, Mueller A. Influence of body mass index on calculated androgen parameters in adult women with hirsutism and PCOS. Exp Clin Endocrinol Diabetes 2007, 115:380-6.
27. Cupisti S, Kajaia N, Dittrich R, Duezenli H, Beckmann MW, Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 2008, 158:711-9.
28. Kajaia N, Binder H, Dittrich R, Oppelt PG, Flor B, Cupisti S, Beckmann MW, Mueller A. Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 2007, 157:499-507.
29. Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome (PCOS) and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 2008, 93:1408-11.
30. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. J Clin Endocrinol Metab 2008, 93:19-25.
31. Gooren LJ. Olympic sports and transsexuals. Asian J Androl 2008, 10:427-32.
32. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999, 276:E317-25.
33. Berra M, Armillotta F, D'Emidio L, Costantin A, Martorana G, Pelusi G, Meriggiola MC. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 2006, 8:725-9.
34. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. J Sex Med 2008, 5:765-76.
35. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf) 2005, 63:280-93.
36. Guéguen R, Jouanny P, Guillemin F, Kuntz C, Pourel J, Siest G. Segregation analysis and variance components analysis of bone mineral density in healthy families. J Bone Miner Res 1995, 10:2017-22.
37. Falch JA. The effect of physical activity on the skeleton. Scand J Soc Med Suppl 1982, 29:55-8.
38. Lewiecki EM. Premenopausal bone health assessment. Curr Rheumatol Rep 2005, 7:46-52.
39. Turner A, Chen TC, Barber TW, Malabanan AO, Holick MF, Tangpricha V. Testosterone increases bone mineral density in female-to-male transsexuals: A case series of 15 subjects. Clin Endocrinol (Oxf) 2004, 61:560-6.
40. Bilezikan JP, Morishima A, Bell J, Brumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998, 339:599-603.
41. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997, 337:91-5.
42. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubhan DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994, 331:1056-61.
43. Lips P, van Kesteren PJ, Asscheman H, Gooren LJ. The effect of androgen treatment on bone metabolism in female-to-male transsexuals. J Bone Miner Res 1996, 11:1769-73.
44. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 1997, 12:1833-43.
45. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999, 84:3626-35.
46. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-74.
47. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997, 100:1755-9.
48. Haraldsen IR, Haug E, Falch J, Egeland T, Opjordsmoen S. Cross-sex pattern of bone mineral density in early onset gender identity disorder. Horm Behav 2007, 52:334-43.
49. Brown MA, Haughton MA, Grant SF, Gunnell AS, Henderson NK, Eisman JA. Genetic control of bone density and turnover: Role of the collagen 1alpha1, estrogen receptor, and vitamin D receptor genes. J Bone Miner Res 2001, 16:758-64.
50. Sosa M, Jódar E, Arbelo E, Domínguez C, Saavedra P, Torres A, Salido E, de Tejada MJ, Hernández D. Bone mass, bone turnover, vitamin D, and estrogen receptor gene polymorphisms in male to female transsexuals: Effects of estrogenic treatment on bone metabolism of the male. J Clin Densitom 2003, 6:297-304.
51. Emi Y, Adachi M, Sasaki A, Nakamura Y, Nakatsuka M. Increased arterial stiffness in female-to-male transsexuals treated with androgen. J Obstet Gynaecol Res 2008, 5:890-7.
52. Van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J, Gooren LJ. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. J Clin Endocrinol Metab 1996, 81:2227-32.
53. Van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998, 48:347-54.
54. Goh HH, Ratnam SS. Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Maturitas 1997, 26:45-52.
55. Sohn M, Bosinski HA. Gender identity disorders: Diagnostic and surgical aspects. J Sex Med 2007, 5:1193-207.
56. Ott J, van Trotsenburg M, Kaufmann U, Schrögendorfer K, Haslik W, Huber JC, Wenzl R. Combined hysterectomy/salpingo-oophorectomy and mastectomy is a safe and valuable procedure for female-to-male transsexuals. J Sex Med 2010, 7:2130-8.